Get access

Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study

Authors

  • J. Montoro,

    1. Unidad de Alergia, Hospital Universitario Arnau de Vilanova, Facultad de Medicina, Universidad Católica de Valencia, Valencia, Spain
    Search for more papers by this author
  • A. Del Cuvillo,

    1. Sección de Rinología, UGC ORL, Hospital de Jérez, Cádiz, Spain
    Search for more papers by this author
  • J. Mullol,

    1. Unitat de Rinologia i Clinica de l'Olfacte, Servei d'Otorinolaringologia, Hospital Clínic, Barcelona, Spain
    2. Immunoal.lèrgia Respiratòria Clínica i Experimental (IRCE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Barcelona, Spain
    Search for more papers by this author
  • X. Molina,

    1. Infociencia Clinical Research, Barcelona, Spain
    Search for more papers by this author
  • J. Bartra,

    1. Servei de Pneumologia i Al.lèrgia, Hospital Clínic, Barcelona, Spain
    Search for more papers by this author
  • I. Dávila,

    1. Servicio de Inmuno-Alergia, Hospital Clínico, Salamanca, Spain
    Search for more papers by this author
  • M. Ferrer,

    1. Departamento de Alergia, Clínica Universitaria de Navarra, Pamplona, Spain
    Search for more papers by this author
  • I. Jáuregui,

    1. Servicio de Alergia, Hospital de Basurto, Bilbao, Spain
    Search for more papers by this author
  • J. Sastre,

    1. Immunoal.lèrgia Respiratòria Clínica i Experimental (IRCE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    2. Servicio de Alergia, Fundación Jiménez Díaz, Madrid, Spain
    Search for more papers by this author
  • A. Valero

    Corresponding author
    1. Immunoal.lèrgia Respiratòria Clínica i Experimental (IRCE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
    2. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Barcelona, Spain
    3. Servei de Pneumologia i Al.lèrgia, Hospital Clínic, Barcelona, Spain
    • Unidad de Alergia, Hospital Universitario Arnau de Vilanova, Facultad de Medicina, Universidad Católica de Valencia, Valencia, Spain
    Search for more papers by this author

  • Edited by: Pascal Demoly

Correspondence

Antonio Valero, Servei de Pneumologia i Al.lèrgia, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain.

Tel.: +34 932275540

Fax: +34 932279813

E-mail: valero@clinic.ub.es

Abstract

Background

A modified allergic rhinitis and its impact on asthma (ARIA) (m-ARIA) criterion to classify the severity of allergic rhinitis (AR) has recently been validated in both treated and untreated adult patients; however, such information in children is lacking. The aim of this study was to validate this m-ARIA severity criterion, which allows for discrimination between moderate and severe AR, in a large pediatric patient sample population.

Methods

The m-ARIA classification categorizes AR severity into mild (no affected items), moderate (1–3 affected items), and severe (all four affected items). We applied this modified criterion to untreated AR pediatric patients aged 6–12 years, through an observational, cross-sectional, and multicenter study. AR symptoms were assessed using the Total Four Symptom Score (T4SS), and the severity was evaluated by both ARIA severity items and visual analogue scale (VAS).

Results

Allergic rhinitis pediatric patients (= 1269) from 271 centers were included. Among them, 59.5% had intermittent and 40.5% persistent disease; 89.9% had moderate/severe AR using the original ARIA (o-ARIA) classification and 59.5% had moderate, while 30.5% had severe AR using the m-ARIA criterion. Using the m-ARIA, significantly higher T4SS and VAS scores were obtained when comparing severe with moderate AR.

Conclusions

The m-ARIA severity classification is a useful clinical tool to discriminate moderate from severe AR among untreated pediatric patients.

Ancillary